Lung cancer combo trial halted after just 5 patients
NCT ID NCT05313009
First seen Jan 06, 2026 · Last updated Jun 05, 2026 · Updated 20 times
Summary
This study tested a combination of two targeted drugs, tarloxotinib and sotorasib, in people with advanced non-small cell lung cancer that has a specific genetic change called KRAS G12C. Participants had already tried other treatments, including a KRAS-targeting drug, and their cancer had gotten worse. The trial was stopped early after enrolling only 5 people, so we don't have clear results on how well the combination works.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Hollings Cancer Center at Medical University of South Carolina
Charleston, South Carolina, 29425, United States
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.